Aligos Therapeutics secures $105M private placement to fund Phase 2 hepatitis B study

Aligos Therapeutics, Inc.

Gross proceeds ~$105M from sale of 2.1M shares, pre-funded warrants (1.9M shares), and warrants (2.0M shares); closing expected Feb 13, 2025.
Combined price $26.0825 per share/warrant; warrants exercisable at $26.02, expire Feb 13, 2032; pre-funded warrants at $0.0001.
Net proceeds to fund ALG-000184 Phase 2 study in chronic hepatitis B; cash runway extended into H2 2026.
Placement led by life sciences investor; Jefferies and Piper Sandler as agents; lead investor gets board nomination rights.
Company to file resale registration statement within 45 days; securities sold in private placement exempt from registration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.